Showing results (261-270 of 319) with videos related to
Sort By:
Pageof 32
Neuroscience|November 1, 1996
Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's diseaseA P Nisbet, D J Eve, A E Kingsbury, et al.Journal of Parkinson'S Disease|August 13, 2013
Putaminal upregulation of FosB/ΔFosB-like immunoreactivity in Parkinson's disease patients with dyskinesiaH S Lindgren, D Rylander, H Iderberg, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 19, 2004
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological studyR Katzenschlager, A Evans, A Manson, et al.Neurology|September 16, 2011
Does levodopa accelerate the pathologic process in Parkinson disease brain?L Parkkinen, S S O'Sullivan, M Kuoppamäki, et al.European Neurology|June 1, 2001
Polymyography combined with time-locked video recording (video EMG) for presurgical assessment of patients with cervical dystoniaA Münchau, G Bahlke, P J Allen, et al.FEBS Letters|November 19, 2002
The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodiesD P Hanger, G M Gibb, R de Silva, et al.Acta Psychiatrica Scandinavica|January 17, 2004
Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT studyJ Serra-Mestres, H A Ring, D C Costa, et al.Clinical Neuropharmacology|May 14, 1998
A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's diseaseD J Brooks, R J Abbott, A J Lees, et al.Brain Research. Molecular Brain Research|February 1, 1995
Tissue pH as an indicator of mRNA preservation in human post-mortem brainA E Kingsbury, O J Foster, A P Nisbet, et al.Neurology|January 12, 2005
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutationN L Khan, C Scherfler, E Graham, et al.Pageof 32